Miguel Correa-Tapia

I came from Ecuador, where I studied Clinical Medicine (UCE, Quito). After that I did a Master in Molecular Bioengineering at BIOTEC (TU Dresden, Germany). I did my thesis under the supervision of Bernard Hoflack, characterizing a Cathepsin K-conditional Cre mouse, a model that can be useful to clarify the function of Osteoclasts as regulators of Osteoblast-precursors chemotaxis.

Currently I’m at IDIBAPS, Barcelona, working in the group of Jorge Ferrer. My project deals with HNF1A happloinsufficiency (MODY3), the most common cause of human monogenic diabetes. The objective of the project is to identify compounds that can be used to treat patients with HNF1A-deficient diabetes, and to understand physiological aspects of HNF1A haploinsufficiency. On the other hand I also work on seeking a seric marker of BCM mass, a biomarker that could be helpful to determine the success of therapeutic strategies designed to enhance beta cell regeneration.